Autologous gamma delta T cell therapy (TC BioPharm)

N/A

Report date: 2022/11/25 17:18:25

Base Information

Drug NameAutologous gamma delta T cell therapy (TC BioPharm)
Drug Alias NameAutologous gamma delta T cell therapy - TC BioPharmGamma-delta T cell therapy (TC BioPharm)Autologous γδ T Lymphocytes (TC BioPharm)γδ T cell therapy (TC BioPharm)ImmuniCell +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTc Biopharm LtdMedinet
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTc Biopharm Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A